Updated efficacy and safety of lenvatinib (LEN) + pembrolizumab (pembro) vs treatment of physician's choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Study 309/KEYNOTE-775 Meeting Abstract
| Authors: | Makker, V.; Colombo, N.; Herraez, A. C.; Monk, B. J.; Mackay, H.; Santin, A. D.; Miller, D. S.; Moore, R. G.; Baron-Hay, S. E.; Ray-Coquard, I. L.; Shapira-Frommer, R.; Ushijima, K.; Yonemori, K.; Kim, Y. M.; Guerra Alia, E. M.; Sanli, U. A.; Huang, J.; McKenzie, J.; Barresi, G.; Lorusso, D. |
| Abstract Title: | Updated efficacy and safety of lenvatinib (LEN) + pembrolizumab (pembro) vs treatment of physician's choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Study 309/KEYNOTE-775 |
| Meeting Title: | ESMO Congress 2022 |
| Journal Title: | Annals of Oncology |
| Volume: | 33 |
| Issue: | Suppl. 7 |
| Meeting Dates: | 2022 Sep 9-13 |
| Meeting Location: | Paris, France |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2022-09-01 |
| Start Page: | S785 |
| End Page: | S786 |
| Language: | English |
| ACCESSION: | WOS:000866211600518 |
| DOI: | 10.1016/j.annonc.2022.07.653 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 525MO -- Source: Wos |
